Navigation Links
Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
Date:9/9/2011

MISSISSAUGA, Ontario, Sept. 9, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE/TSX:VRX), announced today that Valeant mailed to the shareholders of Afexa Life Sciences Inc. ("Afexa") its offer and take-over bid circular in connection with the previously announced friendly offer (the "Offer") for all of the outstanding common shares of Afexa (the "Common Shares") at a price of C$0.71 in cash per Common Share. The Offer expires at 5:00p.m. (Edmonton Time) on October 17, 2011, unless otherwise extended or withdrawn.

The Offer represents a premium of approximately 30% to Afexa's 30-trading day volume weighted average closing price on the Toronto Stock Exchange (TSX) as of August 29, 2011 (the day before the announcement of the Offer), and a premium of 49% over the closing price the day before the announcement of the unsolicited bid of Paladin Labs Inc. The Offer also represents a premium of 29% to the cash consideration and a 49% premium to the alternative share consideration offered under Paladin Labs Inc. unsolicited bid (based on Paladin's closing share price on the TSX on August 29, 2011).

Included in the package mailed to the shareholders of Afexa is the directors' circular prepared by Afexa's board of directors (the "Directors' Circular"), unanimously determining that the Offer is fair and in the best interest of Afexa and its shareholders and recommending that the shareholders of Afexa accept the Offer and tender their Common Shares. In addition, the directors and officers of Afexa and their associates and affiliates who own or control Common Shares have agreed to tender all such Common Shares (including Common Shares issuable upon exercise of in-the-money options) held by them pursuant to lock-up agreements with Valeant, representing in the aggregate 9.30% of the outstanding Common Shares on a fully-diluted basis.

Full details of the Offer are included in
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ill., July 25, 2014 NOT FOR ... OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ... June 30, 2014. "This was another very ... per share above our original guidance and announced plans to ...
(Date:7/25/2014)... BOHEMIA, N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... Pediatrics clinic, GPM Pediatrics, reacts to a recent study, ... adulthood. Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... mothers exposed to severe stress are more likely than others ... occurred months before pregnancy." There were two specific ...
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... , WOONSOCKET, R.I., Oct. 15 CVS/pharmacy announced today ... October 22, in light of manufacturer delays in delivery ... However, MinuteClinic will continue to administer seasonal flu ... the flu season with the supply of vaccine replenished ...
... Cynosure, Inc. (Nasdaq: CYNO ... of light-based aesthetic treatment systems, today announced that the company ... 27, 2009 at 9:00 a.m. ET. , On the call, ... President and Chief Financial Officer Timothy Baker will discuss Cynosure,s ...
Cached Medicine Technology:CVS Caremark Announces Updates to Flu Vaccine Program 2CVS Caremark Announces Updates to Flu Vaccine Program 3Cynosure to Announce Third-Quarter 2009 Financial Results on October 27 2
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 ... review recently updated by Vkool.com, this is ... and safe methods for treating all types ... including:,     Tinnitus due to ... tinnitus ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The U.S. Food ... list that includes a new medication guide for AndroGel to ... serious side-effect of taking the topical low testosterone medication, notes ... AbbVie Inc., the makers of the low testosterone theapy drug, ... of pain, swelling or redness as signs of a blood ...
(Date:7/26/2014)... According to the "Get Rid Tattoo Naturally" ... comprehensive guide that provides readers with safe and natural ... also teaches them how to fade dark colored tattoos, ... own home for drastic results. , Vkool reveals ... includes step-by-step tutorials and product recommendations for treating different ...
(Date:7/25/2014)... 2014 2014 Deep Research ... Chromatography Industry” is a professional and in-depth ... Gel Permeation Chromatography market. The report provides ... Permeation Chromatography definition, classification, application, and industry ... This research covers the international market analysis, ...
(Date:7/25/2014)... A federal judge has denied defense ... Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected as ... go before a jury on September 1, 2014, Bernstein ... 18th, U.S. District Judge Ed Kinkeade of the Northern ... may proceed to trial against Johnson & Johnson, the ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... in brain development that underlie autism spectrum disorder (ASD) ... months, according to research reported online today in the ... associated with ASD (impaired social communication and repetitive behaviors) ... researchers found clear differences in brain communication pathways as ...
... the initial steps that occur in the body when type ... adult. The analysis comes from a team of researchers ... have expertise both in the laboratory and in treating patients. ... 48 hours of their diagnosis with type 1 diabetes, an ...
... -- When it comes to helping Parkinson,s disease patients ... effective than stretching or balance exercises, a new study ... plays an important part in the treatment of Parkinson,s ... director of the Movement Disorder Program at Winthrop-University ...
... DETROIT Ovarian cancer, which killed 15,000 American women ... cancer. A team of Wayne State University School of ... rates in ovarian cancer patients. The "freeze and ... cancerous tumors, said Peter Littrup, M.D., professor of radiology ...
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay News) -- ... heart failure, experts say new treatments have dramatically improved ... patients. "The present environment for heart failure is ... truly remove the term ,failure, from the description of ...
... A mixture of current drugs and carbon nanoparticles shows ... combined with radiation therapy, according to new research by ... Cancer Center. The work blazes a path for ... individual patients. The therapy uses carbon nanoparticles to encapsulate ...
Cached Medicine News:Health News:Researchers see differences in Autism brain development as early as 6 months 2Health News:As diabetes emerges, researchers track disease's first steps 2Health News:As diabetes emerges, researchers track disease's first steps 3Health News:As diabetes emerges, researchers track disease's first steps 4Health News:Weight Training May Help Parkinson's Patients Retain Function 2Health News:Wayne State proves targeted tumor freezing therapy increases ovarian cancer survival 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Nanoparticles may enhance cancer therapy 2Health News:Nanoparticles may enhance cancer therapy 3Health News:Nanoparticles may enhance cancer therapy 4
... applier consists of an applier shaft with attached ... titanium clips. , ,The clip applier jaw ... structure. As the handles of the applier are ... vessel or structure. As the handles are released, ...
... Utilizing a disposable loading unit, the LDS-2™ instrument ... tissue within the cartridge jaw and the knife ... clips. The instrument is activated by squeezing the ... go. The size of the clip is determined ...
... LIGACLIP Clip Applier is a reusable instrument ... clips. This instrument is used with LIGACLIP ... either 316L stainless steel or titanium. The ... tubular structures where a nonabsorbable ligating device ...
SM&trade Single Use Loading Unit with 35 staples available in regular and wide sizes....
Medicine Products: